Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), designed to accelerate artificial intelligence (AI)-driven high-throughput screening for antibody drug discovery. The kit uses advanced cell-free protein synthesis technology for rapid in vitro production of target proteins and antibodies, bypassing the constraints of traditional cell-based expression systems.
The XPressMAX™ kit integrates with AI-powered screening platforms, enabling researchers to identify and optimize antibody candidates more efficiently. Based on an E. coli lysate fully supplemented with transcription and translation components, the kit allows direct protein synthesis from plasmid or PCR templates. It supports the expression of VHH, scFv, Fab, and Miniprotein, which are critical for antibody discovery.
Key highlights include ultra-fast synthesis completed in just 3 hours, a greater than 99% success rate, and support for complex disulfide bonding without additional enhancers, ensuring native folding and bioactivity. Sino Biological has used the kit to establish a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in 3-4 weeks, matching AI's rapid iteration needs.
“Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.”
Dr. Jie Zhang, Sino Biological’s General Manager, added: “AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours.”
The implications for the pharmaceutical industry are substantial. By reducing protein synthesis time from days or weeks to just hours, the kit can significantly cut the cost and time of early-stage drug development. This enables more candidates to be screened rapidly, increasing the likelihood of identifying effective antibodies for diseases ranging from cancer to autoimmune disorders. For researchers, it means faster validation of AI-generated designs and a more efficient pipeline from discovery to preclinical testing.
Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or request a free sample via the provided form.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, the company delivers tailored solutions to researchers in over 90 countries.
